Dr Sunny Nayee talks with The Pharma Letter about the ‘need for societal-level discussion about medical cannabis’

TMCC’s Medical Director Dr Sunny Nayee talks with industry thought leader The Pharma Letter about the need for society to reframe its approach and perspective on the use of medical cannabis for patients in need. 

Dr Nayee says “Research has built over the past two-to-three years, demonstrating that medical cannabis is an efficacious and well-tolerated option for people with chronic pain. 

Recognition at a European level through the European Pain Federation summarizes the evidence, which is growing year-on-year as we see more and more patients demonstrate successful outcomes.

I have seen the positive effects of medical cannabis in many patients over this time, as have many of my colleagues. Within chronic pain, I have seen patients’ lives transformed by access to medical cannabis when they desperately needed help and had felt they had run out of options.

Medical cannabis is very new in the UK and there is still significant stigma faced by patients and prescribing doctors alongside a lack of National Health Service (NHS) reimbursement, which limits options for those who need it most.

We must communicate that medical cannabis is a well-tolerated, efficacious, and regulated treatment.

We need to have a societal-level discussion about the importance of caring for patients with a significant unmet need and the role of medical cannabis in doing this.

This needs to be heard through the highest levels of the NHS and government to remove the stigma and prescribing barriers facing patients.”

Read the full interview with Dr Sunny Nayee here.